DICOTnews August 2025
Sweden is slowly shifting from summer to autumn. But neither cooler days nor darker evenings can halt our forward momentum. Thus, we continue to follow the carefully carved-out development plan with determination, something the market seems to appreciate. I would also like to extend a warm welcome to our 4,000 new shareholders. We greatly value your trust.
Elin Trampe, CEO Dicot Pharma
Phase 2a study completed
Last week, the final participant attended the closing clinic visit. With this, the study is completed. A data review and analysis process now awaits, with results expected to be presented within two to three months.
At the top of the list
We switched to Nasdaq First North ten months ago. In parallel, we are experiencing strong development; during the first half of the year, the share was among the most actively traded, and in August, our market capitalization passed the threshold for mid cap.
Second quarterly report – in print and on film
Read the report, and watch the presentation where CFO Björn Petersson explains, among other things, the advantages of being a debt-free company.
Index giant adds Dicot Pharma
The MSCI Global Micro Cap Index has in recent days added six Swedish companies. Among them Dicot Pharma, which now joins the 6,500 companies worldwide enjoying increased visibility towards institutional investors.
Article on going against the tide
In July, Svenska Dagbladet reported on the challenging climate facing research-based pharmaceutical companies. Dicot Pharma is going against the tide. This article in Omni explains how, and explores the reasons behind it.
Do you want to receive press releases the moment they are published?
If you want to read our press releases as soon as they’re released, click the link below and fill in just two fields.